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Abstract
Background: Neutrophils are increased in the airways and in induced sputum of severe asthma
patients. We determined the expression of activation markers from circulating neutrophils in
severe asthma, and their supressibility by corticosteroids.
Methods: We compared blood neutrophils from mild, moderate-to-severe and severe steroid-
dependent asthma, and non-asthmatics (n = 10 each). We examined the effect of adding or
increasing oral prednisolone (30 mg/day;1 week).
Results: Flow cytometric expression of CD35 and CD11b, but not of CD62L or CD18, was
increased in severe asthma. F-met-leu-phe increased CD11b, CD35 and CD18 and decreased
CD62L expression in all groups, with a greater CD35 increase in severe asthma. In severe steroid-
dependent asthma, an increase in prednisolone dose had no effect on neutrophil markers
particularly CD62L, but reduced CD11b and CD62L on eosinophils. Phorbol myristate acetate-
stimulated oxidative burst and IL-8 release by IL-1β, lipopolysaccharide and GM-CSF in whole
blood from mild but not severe asthmatics were inhibited after prednisolone. There were no
differences in myeloperoxidase or neutrophil elastase release from purified neutrophils.
Conclusion: Because blood neutrophils in severe asthma are activated and are not inhibited by
oral corticosteroids, they may be important in the pathogenesis of severe asthma.
Background
Asthma is characterised by reversible airways obstruction,
bronchial hyperresponsiveness, and chronic inflamma-
tion of the bronchial mucosal lining. Inhaled corticoster-
oids, particularly in combination with long-acting β-
agonists, are efficient in reducing symptoms and exacerba-
tions. However, a proportion of patients with asthma are
not controlled and have persistent symptoms, recurrent
exacerbations and/or persistent airflow obstruction
despite using high doses of inhaled corticosteroids, and
often oral corticosteroids, and long-acting β2-agonist
bronchodilators [1]. This group of patients often termed
severe asthma or therapy-resistant asthma forms a distinct
category of asthma [2,3]. There may be pathophysiologi-
cal mechanisms that are unique for severe asthma com-
pared to mild/moderate asthma [4]. The neutrophil may
be an important inflammatory cell that contributes to the
pathophysiology of severe asthma since increased neu-
trophilic inflammation measured in induced sputum and
in the bronchial submucosa has been reported in such
patients [5-7] Increased neutrophilic inflammation has
also been observed under other asthmatic circumstances
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such as in patients who have died during a sudden-onset
attack and in patients ventilated following an acute severe
exacerbation [8,9]. In addition, increased neutrophils
have been observed in airway submucosal glands in
patients who have died of asthma [10].
Neutrophils may therefore be involved in the pathogene-
sis of asthma through their activation [11-13]. Neutrophil
migration from the circulation into an area of inflamma-
tion involves regulated expression of leucocyte surface
adhesion molecules. L-selectin (CD62L) is important in
the initial attachment of leucocytes to endothelium, and
is rapidly shed after neutrophil activation by proteolytic
cleavage [14]. This is followed by tight adhesion and
transendothelial migration of granulocytes mediated by
β2 integrins, such as CD11b (CR3, or Mac1), one of 3 α-
chain molecules, and CD18, a common β-chain. Neu-
trophil activation is associated with upregulation of
CD11b and CD18 from intracellular storage pools, and
shedding of CD62L. Neutrophils are also a potential
source of inflammatory mediators such as leukotriene B4
(LTB4), and platelet-activating factor (PAF), of enzymes
such as neutrophil elastase, myeloperoxidase and matrix
metalloproteinases (MMP-9), of reactive oxygen species,
and of cytokines such as TNFα and IL-8 [15]. Peripheral
blood neutrophils and eosinophils may be activated or
primed in the circulation of mild asthmatics with regards
to superoxide production, chemotaxis and increased
expression of surface molecules on neutrophils such as
CD35, which mediates the binding and phagocytosis of
C3b-coated particles and immune complexes [16]. Neu-
trophils have been implicated in the development of
bronchial hyperresponsiveness [17]. Neutrophil elastase
has the capacity to induce mucus gland hyperplasia and
mucus secretion) [18] and proliferation or apoptosis of
airway smooth muscle cells [19,20]. Little is known about
the activation status and the role of the circulating neu-
trophil in severe asthma.
Glucocorticoids, an important treatment for asthma, exert
inhibitory effects on neutrophil activation and functions
such as chemotaxis, free radical generation, and adhesion
[21-24]. They also inhibit neutrophil apoptosis, while
decreasing eosinophil survival by increasing eosinophil
apoptosis [25]. Treatment of mild asthmatics with pred-
nisolone induces an increase in neutrophils in the airways
mucosa [26], but in patients with chronic obstructive air-
ways disease, corticosteroids have very little effect on air-
way inflammation [27,28]. In the present study, we have
investigated the expression of the cell-surface molecules
CD11b, CD62L, CD18 and CD35 on resting and stimu-
lated neutrophils, together with respiratory burst activity,
myeloperoxidase and neutrophil elastase release, and IL-8
cytokine levels from blood cells in different categories of
patients with asthma. We have categorised our asthmatics
into a group of severe corticosteroid-dependent asthmat-
ics on both inhaled and oral corticosteroid therapies,
compared to a group of moderate-to-severe asthmatics
only on inhaled corticosteroid therapy and a group of
mild asthmatics. We also studied the effect of oral pred-
Table 1: Clinical characteristics of controls and asthmatic patients
Mild asthma Moderate-to-severe 
asthma
Severe steroid-
dependent asthma
Non-asthma controls
n 1 01 01 01 0
Gender M:F 2:8 4:6 4:6 7:3
Mean age (years) 35.8 47.7 50.9 36
[range] 22–49 31–73 45–66 32–45
FEV1 (% predicted)1 95.8 ± 3.3 66.7 ± 5.0 51.4 ± 3.7 95
[range] 75–112 38.5–85 30–70.7 92–98
Inhaled corticosteroid dose 
(BDP equivalent µg/day)1
0 1,900 ± 100 2,000 ± 0 0
Atopy* 7 10 5 0
Exhaled NO (ppb) 27.1 46.9 30.8 ND
[range] 6.2–94 9.2–102 10.4–65.2
M: male; F: female; NO: nitric oxide; ND: not determined.
*: Atopy defined as positive skin prick test to 2 common aeroallergens
1: Data shown as mean ± SEMRespiratory Research 2006, 7:59 http://respiratory-research.com/content/7/1/59
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nisolone or of an increase in prednisolone dose on these
neutrophil parameters in the severe and in the mild
asthma patients.
Materials and methods
Subjects
We studied 10 patients with mild asthma, 10 with moder-
ate-to-severe asthma, 10 severe steroid-dependent asth-
matics, and 10 healthy non-asthmatic volunteers (Table
1). All asthmatics had a history of episodic dyspnoea,
wheezing and reversible airway obstruction. Asthma was
diagnosed either on the basis of bronchial hyperrespon-
siveness to methacholine with a PC20 < 4 mg/ml when
baseline FEV1 was > 70%, or by demonstrating > 15%
improvement in baseline FEV1 following inhalation of
salbutamol (400 µg) when the FEV1 was < 70%. Normal
subjects had no chest symptoms, with FEV1 > 90% pre-
dicted. All subjects were non-smokers and have never
smoked previously, and asthmatics were stable with no
changes in asthma symptoms and medication for at least
one month, except for the use of short-acting inhaled β2
agonists. No subject had a history of an upper respiratory
tract infection within the previous 6 weeks.
Mild asthmatics had symptoms less than once a week,
requiring only a short-acting inhaled β2-agonist as
needed. Moderate-to-severe asthmatics had asthma symp-
toms requiring daily use of inhaled short-acting β2-ago-
nists and inhaled corticosteroids (beclomethasone
dipropionate 1,000 to 2,000 µg daily or equivalent) via a
metered-dose inhaler, but not requiring chronic oral pred-
nisolone therapy. Severe steroid-dependent asthmatics
were defined as having persistent symptoms with frequent
exacerbations, limited physical activity and frequent
night-time symptoms requiring high dose inhaled corti-
costeroids (beclomethasone dipropionate, 2000 µg/day
or equivalent), and with maintenance oral prednisolone
(> 5 mg per day for at least one year). The mean mainte-
nance dose of oral prednisolone was 14 mg/day (range
10–20 mg/day).
Atopic status was evaluated by skin prick tests to Dermat-
ophagoides pteronyssinus, mixed grass pollen, and cat hair.
FEV1 was measured with a calibrated, dry-wedge spirome-
ter (Vitalograph, Buckingham, UK.). All patients gave
informed consent, and the study was approved by the
Royal Brompton Hospital Ethics Committee.
Effect of prednisolone
The effect of prednisolone on neutrophil function in
peripheral blood was determined by treating mild asthma
patients with prednisolone 30 mg/day for 1 week, and
steroid-dependent patients with a dose of 30 mg/day
added to their usual maintenance dose for one week.
Blood samples were obtained before and on the day after
the seventh dose of prednisolone had been taken. The
study was not blinded or placebo-controlled, but the per-
son analysing the cells ex-vivo was blinded to the treat-
ment received by the asthmatics.
Surface molecule expression
Fluorescein isothiocyanate (FITC)-conjugated mono-
clonal antibodies directed against CD11b, CD62L (L-
selectin), CD35 and CD18, along with the appropriate
isotype controls (Serotec Ltd, Oxford, UK) and phyco-
erythrin (PE)-conjugated CD16 monoclonal antibody
(Becton Dickinson, Oxford, UK) were added to
heparinised whole blood (100 µl) at 4°C for 30 min in
the dark. Cells were washed with phosphate-buffered
saline (PBS, Gibco, Invitrogen, UK) containing 0.5%
bovine serum albumin (BA, Sigma Aldridge, Poole, UK)
and 0.5% sodium azide (Sigma Aldridge, Poole, UK).
After centrifugation (5 minutes; 1800 rpm) the superna-
tant was discarded and 2 ml of freshly-prepared Erythro-
lyse (Serotec Ltd, Oxford, UK) were added (10 min; room
temperature). Cells were then washed with 2 ml PBS-BA
and centrifuged as above and resuspended in 0.5 ml of
0.5% paraformaldehyde (Sigma Chemical Co, Poole,
UK).
Stimulation of whole blood
Blood was incubated with N-formyl-methionyl-leucine-
phenylalanine (FMLP 10-7M, Sigma Aldridge, Poole, UK)
for 10 min at 37°C. The reaction was stopped by adding
cold PBS solution. The tubes were then centrifuged for 5
min at 1800 rpm and the supernatant discarded. Blood
was then incubated with conjugated monoclonal anti-
bodies.
Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35,  and CD18 expression on neutrophils from lysed whole blood  from 10 normal, 10 mild, 10 moderate-to-severe and 10  severe steroid-dependent asthma patients Figure 1
Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35, 
and CD18 expression on neutrophils from lysed whole blood 
from 10 normal, 10 mild, 10 moderate-to-severe and 10 
severe steroid-dependent asthma patients. There was 
increased expression of CD11b and CD35 in severe asth-
matics. Data shown as mean ± SEM. * p < 0.05; ** p = 0.01.
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Flow cytometry
Flow cytometry was performed using a FACScan analyser
(Becton Dickinson, Oxford, UK) with Argon-ion laser.
Fluorescence gain was adjusted using a gate drawn around
the granulocyte population on an unstained lysed whole
blood sample, and then placing this population in the
first log decade. Compensation was set by using blood
incubated with either FITC- or PE-labelled monoclonal
antibodies in order to correct for spectral overlap. As an
instrumental control measure, CaliBRITE beads (Becton
Dickinson) were used to ensure the correct alignment and
calibration of the flow cytometer. Ten thousand events
were collected from each sample. We used the method
described by Gopinath et al for identification of neu-
trophils and eosinophils in lysed whole blood using side
scatter and CD16 negativity [29]. Granulocytes were dis-
criminated from other cell populations by their character-
istic high side and forward light scatter. A gate was drawn
around the granulocytes which was reflected into a dot-
plot of side-scatter and CD16, showing neutrophils as
CD16-positive cells with eosinophils as CD16-negative
cells with high side scatter. Purity of the neutrophil and
eosinophil populations determined was close to 99% on
cytospin preparations, as previously described. A further
gate was then drawn around the neutrophil (CD16+) or
eosinophil (CD16-) populations and reflected into a his-
togram so that cells can be labelled with a further fluoro-
chrome (eg. CD11b or CD18). Results were recorded as
mean fluorescence intensity (MFI) which represents the
cell surface receptor density.
Oxidative burst and elastase measurements
Respiratory burst was measured according to the method
of Rothe and Valet [30]. Briefly, 3 ml of heparinised blood
was layered onto 3 ml of Ficoll Hypaque medium (Amer-
sham Biosciences, UK) and left at room temperature for
45 min. The supernatant (800 µl) was then removed and
transferred to an Eppendorf tube and stored on ice.
Hank's balanced salt solution (HBSS, 1 ml; Sigma
Aldridge, Irvine, UK) was added to 20 µl of cell suspen-
sion and 10 µl of dihydrorhodamine 123 (DHR123, 1 ×
10-3M, Molecular Probes, Upssala, Sweden), and the cells
were incubated for 5 min at 37°C. Phorbol myristate ace-
tate (PMA, Sigma Aldridge, Poole, UK; final concentration
1 µM) was added for 20 min at 37°C. Reagent blank tubes
were prepared by adding only PBS to the cell suspension,
while resting cells were initially incubated with PBS, fol-
lowed by the addition of dihydrorhodamine.
After the final incubation, samples (250 µl) were analysed
immediately on the FACS scanner. The FACS machine was
set up so that unstimulated cells were placed in the first
log decade. DHR 123 reacts with hydrogen peroxide as a
result of the respiratory burst to give rhodamine which
emits a green fluorescence which was measured on the
FL1 channel at a wavelength of 530 nm.
Elastase was also measured according to the method
described by Rothe and Valet [31]. HBSS supplemented
with 10 mM HEPES (Sigma Aldridge, Poole, UK; 1 ml)
was added to 20 µl cell suspension, and 1 µl (N-benzy-
loxycarbonyl-Ala-Ala)2-rhodamine 110 (Molecular
probes, Upssala, Sweden; final concentration 4 µM). The
samples were analysed on the flow cytometer after 20
min.
Whole blood culture
Venous blood was collected in heparinized tubes and
diluted 1:10 with RPMI 1640 (Gibco, Invitrogen, UK)
containing 10% fetal calf serum (FCS), 100 U/ml penicil-
lin, 100 µg/ml streptomycin and 2 mM L-glutamine. The
blood was distributed in 1 ml wells and the plates were
incubated at 37°C with 5% CO2 for 24 hours. In addi-
tion, in duplicate wells, diluted blood was stimulated
with IL-1β (10 ng/ml final concentration), lipopolysac-
charide (LPS 10 ng/ml), and GM-CSF (1 ng/ml) prior to
incubation. The plates were then centrifuged at 1800 rpm
for 5 minutes, following which the supernatants were
removed and frozen at -70°C until analysed.
Myeloperoxidase release from purified neutrophils
Granulocytes were isolated by Ficoll-Hypaque gradient
centrifugation of heparinised whole blood (20 ml). After
centrifugation (2000 rpm; 20°C; 20 min), all the layers
above the red cells were removed and 10 ml PBS and 3 ml
3% Dextran T-500 (Pharmacia Biotech, Uppsala, Sweden)
were added. The supernatant was centrifuged and red cells
were lysed by adding 2 ml 10% HBSS in distilled water for
20 seconds, following which excess HBSS (minimum 12
Mean fluorescence intensity of CD35 expression on neu- trophils from 10 normal, 10 mild, 10 moderate-to-severe and  10 severe steroid-dependent asthma patients before (open  bars) and after (striped bars) stimulation with f-met-leu-phe  (FMLP) Figure 2
Mean fluorescence intensity of CD35 expression on neu-
trophils from 10 normal, 10 mild, 10 moderate-to-severe and 
10 severe steroid-dependent asthma patients before (open 
bars) and after (striped bars) stimulation with f-met-leu-phe 
(FMLP). **p < 0.01, *** p < 0.0001, compared to resting lev-
els; +p = 0.02 compared to level from FMLP-stimulated 
blood from normal volunteers.
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ml) was added and the contents of the tube mixed and
centrifuged at 1800 rpm for 5 minutes. The cells were
washed twice in HBSS (Ca++- and Mg++-free). Granulo-
cytes (1 × 106/ml) were then added to 1 ml wells of a 48-
well plate and incubated with IL-β (10 ng/ml) or PBS for
30 min, and incubated at 37°C under 5% CO2. After each
time-point, the plates were centrifuged (1800 rpm; 5 min)
following which the supernatant was withdrawn and
stored at -70°C until analysed for MPO levels.
Enzyme-linked immunosorbent assay (ELISA)
IL-8 (duoset, R&D systems, Oxon, UK) and neutrophil
myeloperoxidase (MPO; Calbiochem, San Diego, USA)
concentrations were measured in the culture supernatants
with specific immunoassay kits according to the manufac-
turer's instructions. The detection limit was 31.2 pg/ml for
IL-8 and 1.6 ng/ml for MPO.
Statistical analysis
Unless otherwise stated, data are expressed as mean ±
standard error of the mean (SEM). Differences in surface
marker expression between groups were evaluated using
Kruskall Wallis test. Differences between each of the
groups and controls were evaluated using the Mann-Whit-
ney U-test, with application of Bonferroni correction. The
effects of prednisolone therapy or of the stimulation with
various stimulants in vitro were analysed by the Wilcoxon
signed-rank test. A p value of 0.05 or less was considered
to be statistically significant.
Results
Surface molecule expression on lysed whole blood
In unstimulated blood, there was an increased expression
of CD35 and CD11b on neutrophils in patients with
severe steroid-dependent asthma compared to mild and
moderate-to-severe asthmatics, and non-asthmatic volun-
teers (p < 0.05). There were no significant differences in
the expression of CD62L or CD18 between the groups
(Fig 1).
Stimulation of blood with FMLP increased the expression
of CD11b, CD35, and CD18 surface molecules on gated
neutrophils in all groups of patients; there was concomi-
tantly a significant decrease in CD62L in all groups. The
increase in CD35 expression after stimulation with both
FMLP was greater in severe asthmatics compared to that
seen in non-asthmatic volunteers (p = 0.02; Fig 2), but
was not significantly different compared to the other asth-
matic groups.
Prednisolone had no effect on the expression of CD11b,
CD62L, CD35 or CD18 on neutrophils from the 10 severe
corticosteroid-dependent (Fig 3). In the 10 mild asthmat-
ics, there was a significant decrease in the level of CD62L
after prednisolone (Fig 3); this decrease was from a higher
baseline expression of CD62L, though not statistically dif-
ferent from neutrophils from severe asthma patients. In
contrast, no difference was seen in the baseline expression
of the above surface molecules on peripheral blood eosi-
nophils between the patient groups (data not shown).
Following prednisolone, however, there was a significant
reduction in the expression of CD11b and CD62L on eosi-
nophils in both mild and severe patients, and a reduction
in CD18 in mild asthmatics (Fig 4).
Oxidative burst in peripheral blood neutrophils
PMA stimulated the oxidative burst in granulocytes in a
dose-dependent manner, with maximal stimulation
achieved after 20 min (data not shown). The oxidative
burst in mild asthmatics was greater than that in normal
subjects (p = 0.02), while similar levels of oxidative burst
were seen between normal subjects and severe asthma
patients (Fig 5). After prednisolone, the oxidative burst
was reduced in mild asthma patients but not in severe
patients.
Release of IL-8 from whole blood culture
In unstimulated blood, IL-8 was not detectable in serum
in patients with mild or severe asthma but after 24 hours,
IL-8 was detectable. IL-8 levels from mild asthmatics were
not significantly elevated after stimulation with IL-1β,
LPS, and GM-CSF compared to severe asthmatics. In the
Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35  and CD18 expression on blood neutrophils in 10 mild and 9  severe steroid-dependent asthma before (pre) and after  (post) a course of prednisolone or of increased prednisolone  dose (30 mg/day for one week) Figure 3
Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35 
and CD18 expression on blood neutrophils in 10 mild and 9 
severe steroid-dependent asthma before (pre) and after 
(post) a course of prednisolone or of increased prednisolone 
dose (30 mg/day for one week). CD62L expression 
decreased in mild asthmatics following prednisolone, but 
there was no effect in patients with severe asthma. *p < 0.05 
compared to pre-values in mild asthma group.
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mild group, however, there was a significant decrease in
IL-8 production induced by IL-1β, LPS and GM-CSF fol-
lowing prednisolone therapy; this effect of prednisolone
was not seen in the severe group (Fig 6). There were no sig-
nificant differences in the release of IL-8 in the pre-pred-
nisolone blood between the patients mild and severe
asthma.
Neutrophil elastase and myeloperoperoxide release from 
neutrophils
Flow cytometric analysis of whole blood showed no dif-
ference in the baseline level of neutrophil elastase
between mild or severe asthmatics, and there was no sig-
nificant effect of prednisolone on these levels. No signifi-
cant difference was seen in the baseline or IL-β-stimulated
MPO levels in purified blood neutrophils between the
mild and severe asthmatics. There was no significant effect
of prednisolone on the MPO levels in either group.
Discussion
We determined whether circulating neutrophils in
patients with severe asthma exhibited evidence of activa-
tion in terms of expression of surface markers or mediator
release. CD35 and CD11b expression was higher on rest-
ing peripheral blood neutrophils in severe steroid-
dependent asthmatics compared to normal and mild asth-
matics, suggesting that neutrophils are in a more activated
state in the circulation of severe asthmatics. In addition,
CD35 expression on neutrophils from severe asthmatics
was increased further above that seen in normal patients
following stimulation of whole blood with fMLP. No dif-
ference in the expression of these surface molecules was
seen on eosinophils in any of the groups.
In previous studies of neutrophil surface marker expres-
sion in asthma, no differences in expression of CD11b
and CD62L had been observed compared to non-asth-
matic controls [32], although an elevation in CD35 had
been reported [16]. These are in contrast to the current
results showing no significant differences in expression of
CD35, CD11b and CD62L in mild and moderate asth-
matics compared to normal volunteers. However, in this
first study of blood neutrophils in severe asthma, we
found an increase in CD35 and CD11b expression in
patients with severe steroid-dependent asthma. Stimula-
tion of neutrophils with fMLP increased expression of
CD11b on neutrophils and eosinophils to a larger extent
in children with mild asthma than in controls [16]. We
found no such differences in our adults with mild asthma,
but CD35 was slightly more inducible on neutrophils
from severe steroid-dependent asthmatics. The discrepan-
cies between these studies are not clear, but may relate to
the age of the patients, to methodological differences in
assaying these markers and to the grading of severity of
the patients.
The cause of the increase in CD35 and CD11b expression
on neutrophils from patients with severe asthma is
unclear. One confounding factor is that the patients with
severe asthma were on chronic oral prednisolone therapy
which can induce blood neutrophilia attributable to bone
marrow release of neutrophils, and also to mobilisation
of a marginating blood pool [33,34]. Prednisolone treat-
ment of mild asthmatics did not result in an increase in
CD35 or CD11b expression, suggesting that the recruit-
ment of new neutrophil pools may not be the cause of the
increase seen in severe asthma. However, an inhibition in
neutrophil CD62L expression by corticosteroids as
observed in mild asthmatics has been attributed to a direct
inhibition of CD62L expression in the maturation pool of
bone marrow neutrophils [35]. It is likely that the increase
in CD35 and CD11b may be a specific abnormality of cir-
culating neutrophils in severe asthma. An intriguing fea-
ture is that the enhanced expression of CD11b was not
accompanied by a reciprocal increase in the CD18 expres-
sion, since CD11b and CD18 constitute the Mac-1
integrin. On the other hand, it is also possible that there
is enhanced shedding of CD18 or a redistribution of
CD18 complexes with the CD11 family.
One of the problems of doing comparative studies of
these groups of asthmatic patients separated according to
disease severity is that the severe group is usually on
chronic prednisolone therapy and it is difficult to exclude
the effects of such therapy on neutrophil function in the
severe asthma group as accounting for any observed dif-
Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35  and CD18 expression on blood eosinophils in 10 mild and 9  severe steroid-dependent asthmatics before (pre) and after  (post) a course of prednisolone Figure 4
Mean fluorescence intensity (MFI) of CD11b, CD62L, CD35 
and CD18 expression on blood eosinophils in 10 mild and 9 
severe steroid-dependent asthmatics before (pre) and after 
(post) a course of prednisolone. *p < 0.05; **p < 0.01 com-
pared to within-group pre-values.
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ferences. For this reason, we have studied the effect of a
course of high dose prednisolone on blood neutrophil
function, albeit for only one week.
We found no effect of prednisolone on the expression of
CD11b, CD62L, CD35 or CD18 in severe asthma, while,
in mild asthma, prednisolone caused a significant
decrease in CD62L expression without affecting the
expression of CD35, CD11b and CD18. Thus, while the
expression of CD62L by prednisolone was suppressed in
mild asthma, this was not the case in severe asthma. Our
observation in mild asthma patients is consistent with
two reports of reduction in CD62L expression following
intravenous dexamethasone in normal individuals
[36,37]; similarly, high doses of corticosteroids decreased
CD62L and CD11b in patients with multiple sclerosis and
in patients undergoing cardio-pulmonary bypass [38,39].
The reduction of surface molecule CD62L expression by
glucocorticoids may occur on segmented neutrophils
within the maturation pool of the bone marrow but not
on neutrophils already in the circulation [35]. This may be
one mechanism of the anti-inflammatory action of gluco-
corticoids in mild asthma, whereby the initial weak bind-
ing of leucocytes to the endothelium mediated by L-
selectin molecules such as CD62L is reduced. By contrast,
the lack of inhibitory effect of corticosteroids on CD62L
in severe asthmatics may allow granulocyte recruitment
into inflammatory sites to continue. This lack of inhibi-
tory effect appears to be selective for neutrophils since sur-
face molecule expression of CD62L on eosinophils from
both mild and severe patients were reduced by pred-
nisolone to a similar extent. Thus, in severe asthma, blood
eosinophils were sensitive while neutrophils appear to
have lost their sensitivity to the effects of increased oral
dose of prednisolone.
In addition to the loss of the effect of prednisolone on
neutrophil surface markers in severe asthma, there was
also lack of inhibition on the stimulated release of IL-8,
and oxidative burst. Levels of IL-8 after whole blood cul-
ture were not significantly different between mild and
severe steroid-dependent asthmatics, but IL-8 levels from
severe patients were less readily suppressed after a course
of prednisolone compared to mild asthmatics. It must be
noted that although neutrophils stimulated with IL-1β,
LPS and GM-CSF may be an important source of IL-8,
other cells such as monocytes may also be contributory.
We conclude that either of these cells were likely to repre-
sent the site of reduced corticosteroid responsiveness seen
in the blood samples of patients with severe asthma.
The oxidative burst activity of neutrophils was greater in
mild asthmatics compared to normal patients and severe
asthma patients. Furthermore, prednisolone decreased
oxidative burst activity in neutrophils from mild asthmat-
ics, as reported previously in isolated bovine neutrophils
[40], but there was no significant effect in the severe
patients. Prolonged corticosteroid therapy may lead to
inhibition of neutrophil superoxide production, possibly
through inhibition of NADPH oxidation or impairment
of other transduction mechanisms in the respiratory burst
[23]. It is possible that the loss of suppressibility of the
oxidative burst to prednisolone in severe asthma could be
due to the reduced basal release possibly induced by
chronic prednisolone therapy. Examination of the effect
of prednisolone in normal volunteers in whom the base-
line respiratory burst is similar to that of severe asthma
patients would resolve the issue as to whether suppression
is possible.
In comparison to whole blood release, when neutrophils
were purified and studied in vitro, no difference was seen
in the basal or IL-1β stimulated myeloperoxidase release
from purified granulocytes between normal, mild, or
severe asthmatics. The isolation procedure itself may alter
the neutrophil to such an extent as to abolish any differ-
ences in activation. Monocytes are a source of myeloper-
oxidase but we have not studied monocytes in this study.
No difference was seen in peripheral blood neutrophil
elastase levels between mild and severe asthmatics using a
flow cytometric method of analysis. Increased levels of
neutrophil elastase have been reported in sputum from
asthmatics with an exacerbation due to a respiratory tract
infection [41], and in patients in status asthmaticus
Mean fluorescence intensity (MFI) of oxidative burst from  neutrophils stimulated with phorbol myristate acetate (PMA)  in 9 normal volunteers (normal) or in 9 mild and 9 severe  steroid-dependent asthmatics before (pre) and after (post)  prednisolone Figure 5
Mean fluorescence intensity (MFI) of oxidative burst from 
neutrophils stimulated with phorbol myristate acetate (PMA) 
in 9 normal volunteers (normal) or in 9 mild and 9 severe 
steroid-dependent asthmatics before (pre) and after (post) 
prednisolone. Data shown as mean ± SEM. * p < 0.01 com-
pared to pre-values in mild asthma group.
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undergoing mechanical ventilation in the absence of
infection [8,9].
What is the relevance of our findings on circulating blood
neutrophils and on the pathophysiology of the airways of
severe asthma? The lack of inhibition of CD62L expres-
sion and of the release of reactive oxygen species and IL-8
by prednisolone may explain why there may be ongoing
inflammation and asthma in patients with severe asthma.
Heightened expression of CD62L may increase the ability
of the neutrophil to transmigrate from the circulation into
the airway submucosa. Interestingly, the ability of pred-
nisolone to suppress the eosinophil expression of CD11b
and CD62L in severe asthma would indicate that eosi-
nophils may be less likely to contribute to the pathophys-
iological changes in the airways. The lack of inhibition of
IL-8 release would also lead to increased neutrophilic
inflammation since IL-8 is considered to be an important
molecule for the development of neutrophuilic inflam-
mation in asthma. Concentrations of IL-8 are correlated
with neutrophil accumulation in asthmatic airways [7],
and IL-8 is increased in bronchoalveolar lavage fluid and
serum of asthma patients [42,43]. A recent study sug-
gested that neutrophils that have migrated to IL-8 may
subsequently cause eosinophils to accumulate to the asth-
matic airways [44].
Why is the blood neutrophil less responsive to corticoster-
oids? Previous studies on circulating blood cells have
focused on the peripheral blood mononuclear cell as
being the site of corticosteroid resistance [45,46].
Decreased binding affinity of the glucocorticoid receptor
(GR), increased expression of the alternatively-spliced var-
iant GR-β, increased binding of the activated GR receptor
to pro-inflammatory transcription factors such as AP-1
and reduced recruitment of histone deacetylase have all
been implicated as the cellular basis for this resistance to
corticosteroids [45,47-49]. High levels of GR-β have been
reported in neutrophils, and these may be upregulated by
IL-8 [50].
Conclusion
The circulating neutrophil in severe asthma shows evi-
dence of activation, as measured by the increased expres-
sion of the adhesion molecules, CD11b and CD35, and of
resistance to the effects of prednisolone. The neutrophil
may be an important contributor to the inflammatory
process in severe asthma, and further studies are needed
on lung neutrophils to support this notion. The mecha-
nism of loss of corticosteroid inhibition of neutrophils in
severe asthma is not known and deserves further study.
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